miR-15a and 16-1 Are Downregulated in CD4+ T Cells of Multiple Sclerosis Relapsing Patients
miR-15a and 16-1 Are Downregulated in CD4+ T Cells of Multiple Sclerosis Relapsing Patients
复制标题
DOI：
10.3109/00207454.2012.678444
复制
发表时间：
2012-08-01
影响因子：
2.2
通讯作者：
Silva, Wilson Araujo, Jr.
中科院分区：
文献类型：
--
作者：
Cetrulo Lorenzi, Julio Cesar;Brum, Doralina G.;Silva, Wilson Araujo, Jr.
复发缓解型多发性硬化症（RR-MS）的病理学主要归因于激活的自身反应性效应T淋巴细胞。microRNA对免疫应答的影响已被证明发生在淋巴细胞分化和功能的不同途径中。在此，研究了来自RR-MS患者的PBMC、CD 4（+）和CD 8（+）中miRNAs miR-15 a/161的表达。BCL 2是一种已知的miR-15 a/16-1靶标，也已被分析。结果显示，miR-15 a/16-1在CD 4（+）T细胞中下调，而BCL 2仅在RR-MS患者中高表达。我们的数据表明，miR-15 a/16-1也可以调节来自RR-MS患者的CD 4（+）T细胞中的BCL 2基因表达，从而影响凋亡过程。
The pathology of relapsing-remitting multiple sclerosis (RR-MS) is largely attributed to activated autoreactive effector T lymphocytes. The influence of microRNAs on the immune response has been shown to occur in different pathways of lymphocyte differentiation and function. Here, the expression of the miRNAs miR-15a/161 in PBMC, CD4(+), and CD8(+) from RR-MS patients has been investigated. BCL2, a known miR-15a/16-1 target, has also been analyzed. The results have shown that miR-15a/16-1 is downregulated in CD4(+) T cells, whereas BCL2 is highly expressed in RR-MS patients only. Our data suggest that miR-15a/16-1 can also modulate the BCL2 gene expression in CD4(+) T cells from RR-MS patients, thereby affecting apoptosis processes.